PHERECYDES PHARMA has a total of 52 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), Australia and Canada. Its main competitors in its focus markets biotechnology, pharmaceuticals and basic materials chemistry are AMSTERDAM MOLECULAR THERAPEUTICS BV, ASTERIAS BIOTHERAPEUTICS INC and YANSSEN BAJOTEK INK.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 13 | |
#2 | Australia | 7 | |
#3 | Canada | 7 | |
#4 | WIPO (World Intellectual Property Organization) | 7 | |
#5 | United States | 6 | |
#6 | China | 4 | |
#7 | Israel | 4 | |
#8 | Brazil | 2 | |
#9 | France | 1 | |
#10 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Basic materials chemistry | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Measuring microorganism processes | |
#6 | Preservation of human bodies | |
#7 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Pouillot Flavie | 29 |
#2 | Blois Hélène | 19 |
#3 | Iris Francois | 13 |
#4 | Blois Helene | 12 |
#5 | Fevre Cindy | 7 |
#6 | Medina Mathieu | 7 |
#7 | Hélène Blois | 2 |
#8 | Flavie Pouillot | 2 |
#9 | Helene Blois | 1 |
#10 | Cindy Fevre | 1 |
Publication | Filing date | Title |
---|---|---|
EP3372085A1 | Phage therapy | |
EP3018201A1 | Phage therapy | |
EP2893933A1 | Phage Therapy of E coli infections | |
EP2865383A1 | Phage therapy of pseudomonas infections | |
FR2945049A1 | Modification of the genome of a lytic bacteriophage by immobilization of the said bacteriophage in its host bacterium | |
CA2673004A1 | Method for the random diversification of a genetic sequence while preserving the identity of some inner segments of said genetic sequence | |
AU2007346006A1 | Method for the preparation of modified bacteriophages by insertion of random sequences in the targeting proteins of said bacteriophages |